Dr Reddy’s After Revlimid: Can Semaglutide and Biosimilars Power the Next Growth Wave?

For the last few years, Dr. Reddy's Laboratories enjoyed a strong earnings boost from Revlimid generics in the United States. The drug became one of the biggest contributors to the company’s profitability and gave investors confidence that the pharma giant could compete aggressively in complex generics. But the tide is changing quickly.

As competition increases and pricing pressure intensifies in the US market, the company now faces a major transition phase. The big question investors and industry watchers are asking is simple: what comes after Revlimid?

The answer appears to lie in two fast-growing pharmaceutical opportunities — semaglutide and biosimilars.

Dr Reddy’s is positioning itself to reduce dependence on a single blockbuster product and build a broader growth engine that can support long-term expansion. The company’s recent strategy signals a shift from relying heavily on one high-margin drug toward creating a diversified specialty portfolio.

Why Revlimid Was So Important for Dr Reddy’s

Revlimid, the cancer therapy originally developed by Bristol Myers Squibb, turned into a goldmine for generic drugmakers after patent-related opportunities opened up. Dr Reddy’s was among the beneficiaries through its generic version, lenalidomide.

The product significantly boosted the company’s US business over the last few years. Strong pricing, limited competition during the early launch phase, and healthy margins helped Dr Reddy’s deliver impressive profitability.

However, this kind of opportunity rarely lasts forever in the pharmaceutical industry.

As more generic companies enter the market, prices tend to fall sharply. The same trend is now impacting Revlimid sales. Analysts believe the erosion in revenue from the drug will continue over the coming quarters as competition intensifies and market exclusivity weakens.

This transition is important because the US market remains a major revenue contributor for Dr Reddy’s. A slowdown in one of its biggest profit drivers naturally raises concerns about future earnings growth.

The Challenge of Replacing a Blockbuster

Replacing revenue from a blockbuster drug is never easy.

In pharma, companies often enjoy a temporary period of high profits from complex generic launches. But once competitors enter, margins shrink rapidly. To sustain growth, companies must continuously develop new products and invest in future therapies.

That is exactly where Dr Reddy’s current strategy becomes interesting.

Instead of depending solely on traditional generics, the company is expanding aggressively into newer segments that offer stronger long-term potential. Two areas stand out:

• Generic semaglutide products
• Biosimilars

These categories are expected to shape the next phase of growth for many pharmaceutical companies globally.

Semaglutide Could Become a Massive Opportunity

Few drugs have generated as much excitement in recent years as semaglutide.

The molecule, used in blockbuster brands like Ozempic and Wegovy, has transformed the treatment landscape for diabetes and obesity. Demand for weight-loss therapies has exploded worldwide, creating one of the most attractive pharmaceutical markets of the decade.

Dr Reddy’s wants a share of this opportunity.

The company is preparing to launch generic semaglutide products in India and other markets where patent barriers are easing. Reports suggest the company may market its version under the “Obeda” brand name.

What makes this opportunity especially attractive is the sheer size of the potential market.

India alone has millions of diabetes and obesity patients. Branded semaglutide therapies remain expensive for many consumers, creating a huge opening for lower-cost generic alternatives. Analysts expect generic competition to dramatically reduce treatment costs and expand access to patients.

For Dr Reddy’s, semaglutide offers multiple advantages:

1. Large Addressable Market

Unlike niche specialty drugs, obesity and diabetes therapies target massive patient populations. Even modest market share gains can translate into meaningful revenue.

2. Strong Long-Term Demand

Global obesity rates continue to rise, and demand for weight management drugs is expected to remain strong for years.

3. Higher Value Opportunity

Compared to standard generics, injectable therapies like semaglutide can offer relatively better margins and more complex manufacturing advantages.

4. Brand Building Potential

Launching a successful semaglutide product can strengthen Dr Reddy’s position in specialty and chronic care therapies.

Still, competition will not be easy.

Several Indian pharmaceutical companies are preparing their own semaglutide launches. Pricing pressure may emerge quickly once multiple players enter the market. Success will depend on manufacturing scale, supply reliability, doctor adoption, and distribution strength.

Biosimilars Could Be the Bigger Long-Term Story

While semaglutide may capture headlines, biosimilars could become the real long-term growth engine for Dr Reddy’s.

Biosimilars are highly similar versions of complex biologic medicines. Unlike traditional chemical-based generics, biosimilars require advanced manufacturing capabilities, large investments, and stringent regulatory approvals.

That complexity creates higher entry barriers.

For companies capable of competing successfully in biosimilars, the rewards can be substantial.

Dr Reddy’s has been steadily increasing investments in this area. Company leadership has openly highlighted biosimilars and innovation as key pillars of future growth.

Several products are already under development or awaiting regulatory approvals, including biosimilar versions of therapies like abatacept and denosumab.

The biosimilars market offers important advantages:

Higher Entry Barriers

Developing biosimilars is expensive and technically demanding. Fewer competitors mean potentially better pricing power compared to traditional generics.

Global Demand Growth

Healthcare systems worldwide are increasingly adopting biosimilars to reduce treatment costs for expensive biologic medicines.

Better Margins

Successful biosimilar products often deliver stronger profitability than conventional generics.

Strategic Positioning

Building expertise in biologics can help companies move up the pharmaceutical value chain.

For Dr Reddy’s, this shift could gradually reduce dependence on volatile generic opportunities and create a more sustainable growth profile.

The US Business Remains Under Pressure

Even with new growth drivers emerging, the company still faces short-term challenges in the United States.

The US generics market continues to experience pricing pressure across several categories. Competition remains intense, and regulatory timelines can create uncertainty for product launches.

Recent quarterly results reflected these pressures clearly. Revenue and profitability were impacted by lower Revlimid contribution and weakness in certain US products.

Investors are now closely watching whether newer launches can offset these declines quickly enough.

The company’s management remains optimistic about achieving double-digit growth in its core business excluding lenalidomide. But markets will likely need more evidence before confidence fully returns.

Diversification Is Becoming a Priority

One noticeable trend in Dr Reddy’s strategy is diversification.

The company is no longer positioning itself purely as a traditional generics manufacturer. Instead, it is building multiple growth pillars across:

• Consumer healthcare
• Specialty products
• Biosimilars
• Obesity therapies
• Complex injectables
• Emerging markets

This broader strategy may help reduce dependence on any single product category.

For example, the company has also expanded its consumer healthcare presence through acquisitions and portfolio additions. Growth in Europe and emerging markets has helped offset some pressure from the US business.

Such diversification matters because the pharmaceutical industry is inherently cyclical. Companies that rely too heavily on one blockbuster drug often face earnings volatility once exclusivity fades.

What Investors Should Watch Going Forward

The next two to three years could be crucial for Dr Reddy’s transformation story.

Several factors will determine whether the company successfully moves beyond Revlimid dependence.

Semaglutide Execution

Can the company launch competitively priced products while maintaining profitability? Market share and manufacturing scale will be critical.

Biosimilar Approvals

Regulatory approvals in major markets like the US and Europe could become important catalysts for future growth.

Margin Stability

Investors will closely track whether newer products can support margins as Revlimid revenue declines.

Research and Development Efficiency

Dr Reddy’s continues to invest heavily in R&D. The success rate of these investments will influence long-term returns.

Global Expansion

Emerging markets and consumer healthcare could provide additional growth stability.

A Transition Phase, Not a Decline Story

It is important to understand that Dr Reddy’s current phase is not necessarily a decline story. Instead, it looks more like a transition story.

The company benefited enormously from Revlimid during a favorable period. Now, as that opportunity matures, management is attempting to build the next growth cycle.

This transition may create temporary earnings pressure and stock market volatility. But it also opens the possibility of a stronger and more diversified business model in the future.

If semaglutide gains traction and biosimilar launches succeed, Dr Reddy’s could emerge as a much broader pharmaceutical player with exposure to some of the industry’s fastest-growing segments.

That said, execution will be everything.

In pharma, promising pipelines do not automatically guarantee commercial success. Regulatory hurdles, pricing pressure, competition, and supply challenges can all affect outcomes.

Final Thoughts

Dr Reddy’s is entering a new chapter.

The company’s dependence on Revlimid is gradually fading, forcing it to search for fresh growth engines. While the erosion in US generic profits may weigh on short-term performance, the bigger picture is becoming increasingly focused on obesity therapies, biosimilars, and diversified healthcare products.

Semaglutide could provide a major near-to-medium-term opportunity, especially in price-sensitive markets like India. Meanwhile, biosimilars may help the company build a stronger long-term competitive advantage globally.

For investors, the key question is no longer how much Revlimid can deliver. The focus has shifted toward whether Dr Reddy’s can successfully reinvent itself for the next decade of pharmaceutical growth.

And based on its current strategy, the company appears determined to do exactly that.